Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 10-Jun-20 11:19 AM View:  | Bentsur Ron Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 66,346 | -- | -- | (100%) 66.35K to 0 | |
| 10-Jun-20 11:11 AM View: | Zuerblis Kenneth J Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 60,121 | -- | -- | (100%) 60.12K to 0 | |
| 10-Jun-20 11:12 AM View: | Forman Alan S Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 88,298 | -- | -- | (100%) 88.3K to 0 | |
| 10-Jun-20 11:18 AM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Grant | 600,000 | -- | -- | 77% 774.35K to 1.37M | |
| 10-Jun-20 11:22 AM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Grant | 45,000 | -- | -- | 16% 282.88K to 327.88K | |
| 10-Jun-20 11:18 AM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 1,374,350 | -- | -- | (100%) 1.37M to 0 | |
| 10-Jun-20 11:20 AM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 3,024,340 | -- | -- | (100%) 3.02M to 0 | |
| 10-Jun-20 11:20 AM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Grant | 220,000 | -- | -- | 8% 2.8M to 3.02M | |
| 10-Jun-20 11:22 AM View: | Sard Mark Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 51,468 | -- | -- | (100%) 51.47K to 0 | |
| 10-Jun-20 11:15 AM View: | Cline Darren S Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 35,468 | -- | -- | (100%) 35.47K to 0 | |
| 10-Jun-20 11:21 AM View: | Hume Daniel Director | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 35,468 | -- | -- | (100%) 35.47K to 0 | |
| 10-Jun-20 11:22 AM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 327,878 | -- | -- | (100%) 327.88K to 0 | |
| 10-Jun-20 11:17 AM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 10-Jun-20 | Disposition (change in control) | 200,891 | -- | -- | (100%) 200.89K to 0 | |
| 06-May-20 9:31 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 04-May-20 | Sale | 272 | $11.51 | $3,130.72 | (< 1%) 197.93K to 197.66K | |
| 20-Apr-20 6:07 AM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 15-Apr-20 | Sale | 53,618 | $4.88 | $261,656.00 | (2%) 2.86M to 2.8M | |
| 03-Apr-20 9:31 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 01-Apr-20 | Sale | 11,524 | $4.79 | $55,200.00 | (4%) 294.4K to 282.88K | |
| 20-Mar-20 9:30 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 16-Mar-20 | Sale | 2,849 | $3.88 | $11,054.10 | (< 1%) 319.73K to 316.88K | |
| 13-Mar-20 9:31 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 10-Mar-20 | Sale | 36,542 | $4.92 | $179,787.00 | (1%) 2.89M to 2.86M | |
| 13-Mar-20 9:31 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 10-Mar-20 | Sale | 16,704 | $4.91 | $82,016.60 | (2%) 788.47K to 771.76K | |
| 13-Mar-20 9:31 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 10-Mar-20 | Sale | 8,846 | $4.92 | $43,522.30 | (3%) 328.58K to 319.73K | |
| 13-Mar-20 9:31 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 09-Mar-20 | Sale | 9,487 | $5.08 | $48,194.00 | (1%) 797.96K to 788.47K | |
| 13-Mar-20 9:31 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 09-Mar-20 | Sale | 1,266 | $5.00 | $6,330.00 | (< 1%) 199.2K to 197.93K | |
| 13-Mar-20 9:31 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 09-Mar-20 | Sale | 5,011 | $5.08 | $25,455.90 | (2%) 333.59K to 328.58K | |
| 13-Mar-20 9:31 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 09-Mar-20 | Sale | 20,909 | $5.09 | $106,427.00 | (< 1%) 2.92M to 2.89M | |
| 28-Feb-20 9:32 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 25-Feb-20 | Sale | 9,147 | $6.43 | $58,815.20 | (3%) 342.74K to 333.59K | |
| 28-Feb-20 9:32 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 25-Feb-20 | Sale | 24,642 | $6.42 | $158,202.00 | (< 1%) 2.94M to 2.92M | |
| 28-Feb-20 9:31 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 25-Feb-20 | Sale | 11,547 | $6.42 | $74,131.70 | (1%) 809.5K to 797.96K | |
| 14-Feb-20 9:29 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 10-Feb-20 | Grant | 105,939 | -- | -- | 114% 93.26K to 199.2K | |
| 14-Feb-20 9:29 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 10-Feb-20 | Grant | 208,417 | -- | -- | 35% 601.09K to 809.5K | |
| 14-Feb-20 9:28 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 10-Feb-20 | Grant | 107,317 | -- | -- | 46% 235.42K to 342.74K | |
| 14-Feb-20 9:28 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 10-Feb-20 | Grant | 425,274 | -- | -- | 17% 2.51M to 2.94M | |
| 14-Feb-20 9:29 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 07-Feb-20 | Sale | 5,064 | $6.72 | $34,030.10 | (5%) 98.32K to 93.26K | |
| 24-Jan-20 9:31 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 22-Jan-20 | Sale | 22,139 | $7.02 | $155,416.00 | (4%) 623.22K to 601.09K | |
| 10-Jan-20 9:16 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 08-Jan-20 | Sale | 13,228 | $10.37 | $137,174.00 | (2%) 636.45K to 623.22K | |
| 03-Jan-20 5:18 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 27-Dec-19 | Sale | 2,446 | $10.48 | $25,634.10 | (< 1%) 2.52M to 2.51M | |
| 03-Jan-20 5:17 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 27-Dec-19 | Sale | 116 | $10.48 | $1,215.68 | (< 1%) 98.44K to 98.32K | |
| 03-Jan-20 5:19 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 27-Dec-19 | Sale | 2,022 | $10.48 | $21,190.60 | (< 1%) 638.47K to 636.45K | |
| 03-Jan-20 5:18 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 27-Dec-19 | Sale | 197 | $10.48 | $2,064.56 | (< 1%) 235.62K to 235.42K | |
| 03-Jan-20 5:17 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 26-Dec-19 | Sale | 893 | $10.75 | $9,599.75 | (< 1%) 99.33K to 98.44K | |
| 03-Jan-20 5:19 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 26-Dec-19 | Sale | 15,494 | $10.75 | $166,560.00 | (2%) 653.97K to 638.47K | |
| 03-Jan-20 5:18 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 26-Dec-19 | Sale | 1,511 | $10.75 | $16,243.20 | (< 1%) 237.13K to 235.62K | |
| 03-Jan-20 5:18 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 26-Dec-19 | Sale | 18,744 | $10.75 | $201,498.00 | (< 1%) 2.54M to 2.52M | |
| 03-Jan-20 5:19 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 24-Dec-19 | Sale | 24,477 | $10.97 | $268,513.00 | (4%) 678.45K to 653.97K | |
| 03-Jan-20 5:18 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 24-Dec-19 | Sale | 2,388 | $10.97 | $26,196.40 | (< 1%) 239.52K to 237.13K | |
| 03-Jan-20 5:18 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 24-Dec-19 | Sale | 29,613 | $10.97 | $324,855.00 | (1%) 2.57M to 2.54M | |
| 03-Jan-20 5:17 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 24-Dec-19 | Sale | 1,412 | $10.97 | $15,489.60 | (1%) 100.74K to 99.33K | |
| 03-Jan-20 5:18 PM View: | Bergstein Ivan Chief Executive Officer Director | Stemline Therapeutics Inc (STML) | 23-Dec-19 | Sale | 5,225 | $10.58 | $55,280.50 | (< 1%) 2.57M to 2.57M | |
| 03-Jan-20 5:17 PM View: | Francomano Robert Chief Commercial Officer | Stemline Therapeutics Inc (STML) | 23-Dec-19 | Sale | 249 | $10.58 | $2,634.42 | (< 1%) 100.99K to 100.74K | |
| 03-Jan-20 5:19 PM View: | Hoberman Kenneth Chief Operating Officer | Stemline Therapeutics Inc (STML) | 23-Dec-19 | Sale | 4,319 | $10.58 | $45,695.00 | (< 1%) 682.76K to 678.45K | |
| 03-Jan-20 5:18 PM View: | Gionco David Chief Accounting Officer | Stemline Therapeutics Inc (STML) | 23-Dec-19 | Sale | 421 | $10.58 | $4,454.18 | (< 1%) 239.94K to 239.52K |
